Prothena Corp Public (PRTA) Net Cash Flow (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Net Cash Flow of $21.9 million in Q1 2026, up 194.08% quarter-over-quarter from -$23.3 million in Q4 2025, and up 141.03% on a YoY basis from $9.1 million in Q1 2025.
Prothena Corp Public (PRTA) Net Cash Flow (2012 - 2026) Analysis & Trends
Prothena Corp Public's Net Cash Flow history runs 15 years deep, the most recent figure standing at $21.9 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 141.03% year-over-year to $21.9 million; the TTM figure through Mar 2026 stood at -$88.5 million (up 31.91% YoY), while the FY2025 annual figure was -$163.9 million, down 10.12% from the prior year.
- Net Cash Flow was $21.9 million for Q1 2026 at Prothena Corp Public, up from -$23.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $215.6 million in Q4 2022 to a low of -$72.3 million in Q1 2024.
- Historically, Net Cash Flow has averaged -$14.7 million across 5 years, with a median of -$34.2 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow surged 1126.65% in 2022, then sank 480.64% in 2024.
- A 5-year view of Net Cash Flow shows it stood at $215.6 million in 2022, then slumped by 124.15% to -$52.1 million in 2023, then grew by 8.05% to -$47.9 million in 2024, then surged by 51.31% to -$23.3 million in 2025, then soared by 194.08% to $21.9 million in 2026.
- The last three Net Cash Flow figures came in at $21.9 million (Q1 2026), -$23.3 million (Q4 2025), and -$40.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 21.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.93 Mn |
| Mar 31, 2026 | 21.93 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Sep 30, 2025 | -40.59 Mn |
| Sep 30, 2025 | -40.59 Mn |
| Jun 30, 2025 | -46.50 Mn |
| Jun 30, 2025 | -46.50 Mn |
| Mar 31, 2025 | -53.45 Mn |
| Mar 31, 2025 | -53.45 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Sep 30, 2024 | -44.86 Mn |
| Sep 30, 2024 | -44.86 Mn |
| Jun 30, 2024 | 16.26 Mn |
| Jun 30, 2024 | 16.26 Mn |
| Mar 31, 2024 | -72.32 Mn |
| Mar 31, 2024 | -72.32 Mn |
| Dec 31, 2023 | -52.07 Mn |
| Dec 31, 2023 | -52.07 Mn |